Resonate Blends, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Resonate Blends, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $943.7K | Jun 20, 2018 |
| FY2017 | Dec 31, 2016 | $458.3K | Jun 20, 2018 |
| FY2016 | Dec 31, 2015 | $116.3K | Apr 24, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.90M | Jul 7, 2025 |
| FY2024 | Dec 31, 2023 | $16.5K | Jul 7, 2025 |
| FY2023 | Dec 31, 2022 | $49.5K | Apr 16, 2024 |
| FY2021 | Dec 31, 2021 | $19.5K | Apr 18, 2022 |
| FY2019 | Dec 31, 2019 | $1.05M | May 14, 2020 |
| FY2019 | Dec 31, 2018 | $1.07M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $943.7K | May 20, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $317.5K | May 31, 2016 |
| FY2015 | Dec 31, 2014 | $342.3K | May 31, 2016 |
| FY2014 | Dec 31, 2013 | $339.5K | Apr 15, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.24M | Jul 7, 2025 |
| FY2024 | Dec 31, 2023 | ($97.7K) | Jul 7, 2025 |
| FY2023 | Dec 31, 2022 | $16.4K | Apr 16, 2024 |
| FY2021 | Dec 31, 2021 | $12.6K | Apr 18, 2022 |
| FY2019 | Dec 31, 2019 | $657.5K | May 14, 2020 |
| FY2019 | Dec 31, 2018 | $751.8K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $626.4K | May 20, 2019 |
| FY2017 | Dec 31, 2016 | $355.2K | Jun 20, 2018 |
| FY2016 | Dec 31, 2015 | $201.1K | Apr 24, 2017 |
| FY2015 | Dec 31, 2014 | $188.5K | May 31, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($2.13M) | Jul 7, 2025 |
| FY2024 | Dec 31, 2023 | ($1.42M) | Jul 7, 2025 |
| FY2023 | Dec 31, 2022 | $653.6K | Apr 16, 2024 |
| FY2021 | Dec 31, 2021 | $623.8K | Apr 18, 2022 |
| FY2021 | Dec 31, 2020 | $201.0K | Apr 18, 2022 |
| FY2021 | Mar 31, 2020 | ($1.94M) | Apr 18, 2022 |
| FY2020 | Dec 31, 2019 | ($3.67M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($339.8K) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($7.65M) | May 20, 2019 |
| FY2017 | Dec 31, 2016 | ($3.32M) | Jun 20, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($1.70M) | Jul 7, 2025 |
| FY2024 | Dec 31, 2023 | ($399.2K) | Jul 7, 2025 |
| FY2023 | Dec 31, 2022 | ($1.39M) | Apr 16, 2024 |
| FY2021 | Dec 31, 2021 | ($428.4K) | Apr 18, 2022 |
| FY2021 | Dec 31, 2020 | ($368.5K) | Apr 18, 2022 |
| FY2020 | Dec 31, 2019 | ($3.18M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($306.7K) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($6.55M) | May 20, 2019 |
| FY2017 | Dec 31, 2016 | ($910.6K) | Jun 20, 2018 |
| FY2016 | Dec 31, 2015 | ($3.01M) | Apr 24, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $61.9K | Jul 7, 2025 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $181.9K | May 14, 2020 |
| FY2019 | Dec 31, 2018 | $132.9K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $114.8K | May 20, 2019 |
| FY2017 | Dec 31, 2016 | $1.18M | Jun 20, 2018 |
| FY2016 | Dec 31, 2015 | $3.21M | Apr 24, 2017 |
| FY2015 | Dec 31, 2014 | $426.8K | May 31, 2016 |
| FY2014 | Dec 31, 2013 | $346.8K | Apr 15, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($1.03M) | Jul 7, 2025 |
| FY2024 | Dec 31, 2023 | $11.2K | Jul 7, 2025 |
| FY2023 | Dec 31, 2022 | ($1.43M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($2.78M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($1.38M) | Apr 19, 2022 |
| FY2020 | Dec 31, 2019 | ($790.9K) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($54.1K) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($145.7K) | May 20, 2019 |
| FY2017 | Dec 31, 2016 | ($433.3K) | Jun 20, 2018 |
| FY2016 | Dec 31, 2015 | ($381.5K) | Apr 24, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $36.0K | Apr 17, 2023 |
| FY2020 | Dec 31, 2020 | $1.0K | Apr 15, 2021 |
| FY2019 | Dec 31, 2019 | $1.0K | May 14, 2020 |
| FY2018 | Dec 31, 2018 | $1.0K | May 20, 2019 |
| FY2015 | Dec 31, 2014 | $2.2K | May 31, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.85M | Jul 7, 2025 |
| FY2024 | Dec 31, 2023 | $992.3K | Jul 7, 2025 |
| FY2023 | Dec 31, 2022 | $399.1K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $301.0K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $169.0K | Apr 19, 2022 |
| FY2020 | Dec 31, 2019 | $130.8K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $533.7K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $510.6K | May 20, 2019 |
| FY2017 | Dec 31, 2016 | $458.1K | Jun 20, 2018 |
| FY2016 | Dec 31, 2015 | $65.2K | Apr 24, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $3.13M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $1.55M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $4.40M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.17M | Apr 19, 2022 |
| FY2020 | Dec 31, 2019 | $718.1K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $617.9K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $983.7K | May 20, 2019 |
| FY2017 | Dec 31, 2016 | $1.70M | Jun 20, 2018 |
| FY2016 | Dec 31, 2015 | $1.17M | Apr 24, 2017 |
| FY2015 | Dec 31, 2014 | $402.4K | May 31, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($3.20M) | Jul 7, 2025 |
| FY2024 | Dec 31, 2023 | ($2.14M) | Jul 7, 2025 |
| FY2024 | Dec 31, 2022 | ($1.15M) | Jul 7, 2025 |
| FY2023 | Dec 31, 2021 | ($4.10M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2020 | ($996.3K) | Apr 17, 2023 |
| FY2021 | Dec 31, 2019 | ($587.2K) | Apr 19, 2022 |
| FY2020 | Dec 31, 2018 | ($84.2K) | Apr 15, 2021 |
| FY2019 | Dec 31, 2017 | ($473.2K) | May 14, 2020 |
| FY2018 | Dec 31, 2016 | ($1.24M) | May 20, 2019 |
| FY2017 | Dec 31, 2015 | ($1.10M) | Jun 20, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($28.87M) | Jul 7, 2025 |
| FY2024 | Dec 31, 2023 | ($26.74M) | Jul 7, 2025 |
| FY2023 | Dec 31, 2022 | ($25.32M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($25.97M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($21.10M) | Apr 19, 2022 |
| FY2020 | Dec 31, 2019 | ($19.16M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($15.49M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($15.15M) | May 20, 2019 |
| FY2017 | Dec 31, 2016 | ($7.50M) | Jun 20, 2018 |
| FY2016 | Dec 31, 2015 | ($4.18M) | Apr 24, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $8.0K | Jul 7, 2025 |
| FY2024 | Dec 31, 2023 | $6.9K | Jul 7, 2025 |
| FY2023 | Dec 31, 2022 | $64.4K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $12.9K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $114.3K | Apr 19, 2022 |
| FY2020 | Dec 31, 2019 | $3.1K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $68.5K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $10.2K | May 20, 2019 |
| FY2017 | Dec 31, 2015 | $61.1K | Jun 20, 2018 |
| FY2016 | Dec 31, 2014 | $4.8K | Apr 24, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Jul 7, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Jul 7, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Jul 7, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Jul 7, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 110.40M | Jul 7, 2025 |
| FY2024 | Dec 31, 2023 | 86.62M | Jul 7, 2025 |
| FY2023 | Dec 31, 2022 | 75.44M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 45.05M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 29.77M | Apr 19, 2022 |
| FY2020 | Dec 31, 2019 | 17.15M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | 2.44M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | 2.44M | May 20, 2019 |
| FY2017 | Dec 31, 2016 | 199,403 | Jun 20, 2018 |
| FY2016 | Dec 31, 2015 | 109.54M | Apr 24, 2017 |